Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rituximab (Mabthera®) as Single Agent and in Combination With Interferon Alfa-2a (Roferon-A®), a Phase-III Randomized Trial in Patients With Follicular or Other CD20+ Low-grade (Indolent) Lymphoma

NCT01609010 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01609010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01609010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rituximab (Mabthera®) as Single Agent and in Combination With Interferon Alfa-2a (Roferon-A®), a Phase-III Randomized Trial in Patients With Follicular or Other CD20+ Low-grade (Indolent) Lymphoma
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2002
Completion date
July 31, 2011
Enrollment
313 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma